Vectracor
VectraCor is a private Totowa, NJ medical device company that sells FDA-cleared ECG, Holter, spirometer, and ABPM devices built on its patented Cardiac Electrical Biomarker (CEB) algorithm, serving hospitals, emergency departments, primary care, cardiology, and veterinary practices through direct sales, distributors, OEM partners, and a Vizient GPO contract.
- Company typePrivate
- Founded2009
- HeadquartersTotowa, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vectracor does
VectraCor, Inc. is a privately held medical device company founded in 2009 and headquartered in Totowa, New Jersey. The company designs and commercializes cardiac and pulmonary diagnostic devices built around its patented Cardiac Electrical Biomarker (CEB®) algorithm — a proprietary index that measures the di-polarity of the cardiac electrical field to flag ECG changes suggestive of acute myocardial infarction. The core product, VectraplexECG, derives a 12-22 lead ECG from only five electrodes and runs on off-the-shelf laptops or tablets, alongside a broader portfolio that includes the Universal SmartECG, V300 Holter Monitor, Orbit Spirometer, 24-Hour ABPM, Office Medic software, and a veterinary Holter variant. All products are FDA cleared, CE marked, and manufactured under ISO 13485, with patents granted in 12+ countries.
The company monetizes primarily through one-time hardware/perpetual-software sales plus recurring extended-warranty subscriptions and consumables (electrodes, spirometry mouthpieces, filters, ABPM cuffs), supplemented by OEM/private-label licensing of ECG and spirometry modules. Distribution runs through direct US sales representatives, independent reps and distributors, a Vizient GPO contract (awarded June 2018), the legacy QRS Diagnostic international network in Europe and Australia (acquired December 2014), and an OEM partner program with an SDK for embedded integrations. End markets span hospitals, emergency departments, urgent care, primary care, cardiology, and veterinary practices, with clinical validation anchored by 40+ peer-reviewed publications and a Medical Advisory Board that includes KOLs from Duke University, Baylor College of Medicine, and Geisinger.
The business remains small (11-50 employees), founder-led (CEO Brad S. Schreck and CMO David M. Schreck), and is funded by operating cash flow plus an early NJEDA grant rather than institutional venture capital. Revenue is not disclosed, and the current growth signals — a 2023 Holter launch, a 2025 software release, active US sales-force buildout, and new OEM and veterinary channels — suggest incremental expansion of product surface and distribution rather than rapid scaling.
Vectracor firmographics
Firmographics- Name
- Vectracor
- Legal name
- VectraCor, Inc.
- Website
- http://www.vectracor.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VectraCor is a private Totowa, NJ medical device company that sells FDA-cleared ECG, Holter, spirometer, and ABPM devices built on its patented Cardiac Electrical Biomarker (CEB) algorithm, serving hospitals, emergency departments, primary care, cardiology, and veterinary practices through direct sales, distributors, OEM partners, and a Vizient GPO contract.
- Ownership category
- akta.pro rank
Vectracor industry classification
Industry- Product category
- Cardiac and Pulmonary Diagnostic Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
- akta.pro secondary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where Vectracor is headquartered
LocationHeadquarters
- HQ city
- Totowa
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Vectracor business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations
Revenue model
- Medical Device Hardware Sales: VectraCor generates revenue from selling medical diagnostic devices including ECG systems (VectraplexECG, Universal SmartECG), Holter monitors (V300), spirometers (Orbit), ABPM monitors, and related accessories and consumables.
- Software Licenses and Subscriptions: The company sells Office Medic software and VectraplexECG software with annual licensing and software updates included under warranty. Extended warranty options provide additional years of software downloads.
- OEM/Private Label Licensing: VectraCor offers OEM electrocardiography and spirometry modules for strategic partners seeking private label opportunities, creating licensing revenue streams.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | VectraplexECG hardware and software packages |
| One time/ perpetual license | Multi-year contract | V300 Holter Monitor with software tiers |
| One time/ perpetual license | Multi-year contract | Orbit Spirometer with Office Medic |
| Subscription | Annual | Extended Hardware Warranty Options |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels6 records
Vectracor product offering
Product offeringCore offering
VectraCor designs, develops, and commercializes medical diagnostic devices that transform off-the-shelf computers and tablets into cardiac and pulmonary diagnostic equipment. Its core offering is the VectraplexECG System featuring the patented Cardiac Electrical Biomarker (CEB®), which detects ECG changes suggestive of acute myocardial infarction and derives a 12-22 lead ECG using only 5 electrodes. The company also offers the Universal SmartECG, V300 Holter Monitor, Orbit Spirometer, 24-Hour ABPM, and the Office Medic software platform, all FDA cleared and CE marked.
Product overview
VectraCor develops and commercializes a portfolio of medical diagnostic devices for cardiology and pulmonology. The core product is the VectraplexECG system featuring patented Cardiac Electrical Biomarker (CEB) technology that detects ECG changes suggestive of heart attacks. The product line includes ECG devices (VectraplexECG with CEB, Universal SmartECG), the V300 Holter Monitor (24hr-7day recording), Orbit Spirometer, and 24-Hour ABPM, all running on Office Medic unified software platform. QRS Diagnostic was acquired in 2014 and operates as a VectraCor company. Products are FDA cleared, CE marked, and manufactured under ISO-13485 certification.
Differentiator
Problem solved
Functional benefit
Brands
- VectraplexECG: ECG system featuring the CEB (Cardiac Electrical Biomarker) technology that can detect ECG changes suggestive of a heart attack and derive a 15-22 lead ECG using only 5 electrodes.
- Universal SmartECG
- V300 Holter
- Orbit Spirometer
- Office Medic
- VB Filter for Orbit
- 24 Hour-ABPM
Products and services
- VectraplexECG System PC-based ECG system with patented Cardiac Electrical Biomarker (CEB®) technology that detects ECG changes suggestive of acute myocardial injury including AMI. Derives 12 to 22-lead ECG using only 5 electrodes. Targeted at hospitals, emergency departments, and cardiology practices.
- Universal SmartECG
Quantifiable outcome
- CEB® shows positive response to balloon and stent inflation during PCI with strong correlation (Henry Ford Health System study, ACC 2017)
- +2 more outcomes
Companies that use Vectracor
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
Vectracor technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Vectracor partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and strategic.
- Vizient, Inc.coreIn June 2018, VectraCor received an Innovative Technology contract from Vizient, the largest member-driven healthcare performance improvement company in the country. The contract was based on recommendation by hospital experts serving on Vizient's member-led councils. Innovative Technology contracts are reserved for technologies that enhance clinical care or patient safety and improve care delivery and business models. This provides VectraCor access to Vizient's member hospital network for product evaluation and purchasing.
- QRS DiagnosticcoreIn December 2014, VectraCor acquired QRS Diagnostic, a healthcare technology and medical supplies provider. Following the closing, the company does business as 'QRS Diagnostic – A VectraCor Company.' VectraCor retained staff and an office in Minnesota while moving some functions to New Jersey. The acquisition combined VectraCor's innovative CEB® cardiac technology with QRS's established ECG and spirometry product portfolio and distribution network in Europe, Australia, and the United States.
- Johns Hopkins UniversitystrategicJohns Hopkins conducted a published study comparing the CEB® to high sensitivity troponin blood test/cardiac serum markers. Presented at ACC 2014 in San Francisco, CA. Published in Critical Pathways in Cardiology – Volume 13, Number 1, March 2014. The study showed association between HsTnI values and CEB® values, suggesting myocardial injury is associated with acute changes in the CEB®.
- Henry Ford Health SystemstrategicHenry Ford Health System conducted a prospective study in the Cardiac Cath Lab. Study presented at the American College of Cardiology Conference (ACC) in Washington, DC in March 2017. Conclusions showed the CEB® shows a positive response to balloon and stent inflation during PCI with a strong correlation.
- University of BaselstrategicUniversity of Basel is a leading research facility worldwide on cardiac serum markers. Conducted studies on CEB® as a novel marker diagnosing myocardial injury in patients with symptoms suggestive for NSTEMI. Presented at AHA November 2017 (published in Circulation) and European Society of Cardiology Conference in Rome September 2016.
- Medical Advisory Board (KOL Network)coreVectraCor has a strong Medical Advisory Board including: Dr. Mitchell W. Krucoff (Duke University - Professor of Medicine/Cardiology, Director Cardiovascular Devices Unit), Dr. Terry D. Bauch (Geisinger Wyoming Valley Medical Center), Dr. W. Frank Peacock (Baylor College of Medicine), and Dr. David M. Schreck (Summit Medical Group). These Key Opinion Leaders provide clinical validation and guidance.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Vectracor competitors and assessment
Company assessmentBroad incumbents
- GE Healthcare: Manufacturer of MAC series resting ECG, IntelliVue patient monitoring, and a broader hospital diagnostic portfolio. Operates in the same clinical diagnostic space as VectraCor across cardiology, hospital monitoring, and ambulatory ECG, with substantially larger sales, R&D, and installed-base resources that create structural advantages.
- Philips: PageWriter resting ECG, IntelliVue patient monitoring, and broader cardiac/telehealth portfolio (including the BioTelemetry acquisition) compete directly with VectraCor's diagnostic cardiology offering. As a major medtech incumbent, Philips has established hospital and ambulatory relationships plus remote cardiac monitoring services that create structural advantages.
Direct peers
- Spacelabs Healthcare: Manufacturer of ECG, Holter monitoring, and ambulatory recording products serving hospitals and clinical research, including Lifecard and Holter analysis systems. Overlapping clinical use cases in cardiac rhythm assessment, ambulatory monitoring, and patient telemetry with VectraCor's V300 Holter and ECG systems.
- Mindray: Chinese medical device manufacturer offering ECG, patient monitoring, and vital signs monitors spanning primary care through hospital segments. Similar multi-modality approach, ISO-certified manufacturing, and global regulatory positioning as VectraCor, with overlapping product lines in resting ECG, Holter, and patient monitoring.
- Schiller AG: Swiss-based ECG, Holter, spirometry, and cardiopulmonary diagnostic manufacturer with a product portfolio and size tier very similar to VectraCor, including 12-lead ECG, Holter analysis, PC-based cardio-spiro systems, and stress testing. Competes head-to-head across Europe, the US, and globally in hospital, primary care, and emergency markets.
- Hillrom (Baxter International): Baxter acquired Hillrom in 2021 and inherited Welch Allyn and Mortara Instrument product lines - ECG, Holter, and stress ECG systems that directly compete with VectraCor's portfolio in hospital and primary care settings with the same FDA 510(k)/CE regulatory pathways and the same target customers (ED, cardiology, primary care).
- Fukuda Denshi: Japanese ECG, Holter, and cardiopulmonary diagnostic manufacturer with a product portfolio nearly identical to VectraCor's, including the CardioMax and FX-7200 ECG lines. Competes globally in hospital and clinical markets, including FDA-cleared ECG and Holter systems sold in the US through distributor networks.
- Midmark: Primary care and integrated office-based diagnostic equipment provider including IQmark resting ECG, vital signs monitors, and spirometry. Very similar go-to-market and customer segment (primary care, urgent care) to VectraCor's Universal SmartECG, Holter, and Office Medic offerings, with overlapping channel through office-based physician practices.
Emerging players
- iRhythm Technologies: Maker of the Zio long-term continuous ambulatory cardiac monitor that directly competes with VectraCor's V300 Holter in ambulatory ECG and arrhythmia detection. Cloud-native architecture, AI-based arrhythmia classification, and patient-friendly patch form factor represent a fundamentally different (and arguably superior) approach for clinical ambulatory use, putting VectraCor's PC-based Holter at a disadvantage.
- CardioComm Solutions: ECG interpretation software and remote cardiac monitoring services company with overlapping software/services approach to VectraCor's CEB® biomarker offering and Office Medic platform. Competes in remote ECG monitoring adjacent to VectraCor's recurring software revenue and represents an alternative ECG software stack for OEM partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Vectracor social profiles
Digital presenceVectracor compliance and trust
Trust signalCompliance4 records
Vectracor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vectracor leadership team
Management profileNumber of profiles
Profiles5 records
Vectracor subsidiaries and ownership
Company hierarchySubsidiaries1 record
Vectracor funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vectracor M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vectracor
What does Vectracor do?
VectraCor designs, develops, and commercializes medical diagnostic devices that transform off-the-shelf computers and tablets into cardiac and pulmonary diagnostic equipment. Its core offering is the VectraplexECG System featuring the patented Cardiac Electrical Biomarker (CEB®), which detects ECG changes suggestive of acute myocardial infarction and derives a 12-22 lead ECG using only 5 electrodes. The company also offers the Universal SmartECG, V300 Holter Monitor, Orbit Spirometer, 24-Hour ABPM, and the Office Medic software platform, all FDA cleared and CE marked.
Is Vectracor a public or private company?
Vectracor is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Vectracor founded?
Vectracor was founded in 2009. It employs 11 to 50 people.
Where is Vectracor based?
Vectracor is headquartered in Totowa, United States, in the North America region.
How does Vectracor make money?
Three revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are software Licenses and Subscriptions and OEM/Private Label Licensing.
Who are Vectracor's main competitors?
Broad incumbents on record are GE Healthcare and Philips. Direct peers are Spacelabs Healthcare, Mindray, Schiller AG, Hillrom (Baxter International), Fukuda Denshi and Midmark. Emerging players are iRhythm Technologies and CardioComm Solutions.
Does Vectracor have an API?
No public API is recorded for Vectracor.
What industry is Vectracor in?
Vectracor's product category is Cardiac and Pulmonary Diagnostic Medical Devices. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 334510 and its SIC code is 3845.